Astria Therapeutics, Inc. (ATXS)
Jan 26, 2026 - ATXS was delisted (reason: acquired by BCRX)
12.58
0.00 (0.00%)
Inactive · Last trade price on Jan 22, 2026
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Astria Therapeutics stock had an average target of 24.33, with a low estimate of 13 and a high estimate of 47.
Price Target: $24.33 (+93.40%)
Analyst Consensus: Hold
* Price targets were last updated on Oct 15, 2025.
Analyst Ratings
The average analyst rating for Astria Therapeutics stock from 6 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 3 | 2 | 2 | 1 |
| Hold | 0 | 0 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 16, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $28 → $13 | Buy → Hold | Downgrades | $28 → $13 | +3.34% | Oct 15, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $30 → $13 | Strong Buy → Hold | Downgrades | $30 → $13 | +3.34% | Oct 14, 2025 |
Financial Forecast
Revenue This Year
8.74M
Revenue Next Year
3.57M
from 8.74M
Decreased by -59.15%
EPS This Year
-2.20
from -1.68
EPS Next Year
-2.27
from -2.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 16.8M | 8.4M | ||||
| Avg | 8.7M | 3.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -3.9% | ||||
| Avg | - | -59.2% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.94 | -1.73 | ||||
| Avg | -2.20 | -2.27 | ||||
| Low | -2.48 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.